Evan David Seigerman
Stock Analyst at BMO Capital
(4.53)
# 323
Out of 4,496 analysts
23
Total ratings
60%
Success rate
28.53%
Average return
Main Sectors:
Top Industries:
11 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MORF Morphic Holding | Downgrades: Market Perform | $52 → $57 | $56.52 | +0.85% | 3 | Jul 9, 2024 | |
| NVO Novo Nordisk | Maintains: Outperform | $163 | $131.54 | +23.92% | 2 | Jun 25, 2024 | |
| GPCR Structure Therapeutics | Maintains: Outperform | $83 → $100 | $37.44 | +167.09% | 2 | Jun 7, 2024 | |
| AMGN Amgen | Maintains: Outperform | $336 → $355 | $331.29 | +7.16% | 3 | May 3, 2024 | |
| PFE Pfizer | Reiterates: Outperform | $33 → $36 | $29.97 | +20.12% | 4 | May 2, 2024 | |
| ABBV AbbVie | Maintains: Outperform | $195 → $180 | $172.32 | +4.46% | 2 | Apr 29, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,055 → $1,082 | $1,063.60 | +1.73% | 3 | Feb 5, 2024 | |
| MRK Merck & Co. | Upgrades: Outperform | $132 | $125.77 | +4.95% | 1 | Oct 27, 2023 | |
| CADL Candel Therapeutics | Maintains: Outperform | $9 → $3 | $6.01 | -50.08% | 1 | May 15, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $40 → $70 | $9.89 | +607.79% | 1 | Dec 12, 2022 | |
| LLY Eli Lilly | Maintains: Outperform | $369 → $396 | $857.47 | -53.82% | 1 | Sep 6, 2022 |
Morphic Holding
Jul 9, 2024
Downgrades: Market Perform
Price Target: $52 → $57
Current: $56.52
Upside: +0.85%
Novo Nordisk
Jun 25, 2024
Maintains: Outperform
Price Target: $163
Current: $131.54
Upside: +23.92%
Structure Therapeutics
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $37.44
Upside: +167.09%
Amgen
May 3, 2024
Maintains: Outperform
Price Target: $336 → $355
Current: $331.29
Upside: +7.16%
Pfizer
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $29.97
Upside: +20.12%
AbbVie
Apr 29, 2024
Maintains: Outperform
Price Target: $195 → $180
Current: $172.32
Upside: +4.46%
Regeneron Pharmaceuticals
Feb 5, 2024
Maintains: Outperform
Price Target: $1,055 → $1,082
Current: $1,063.60
Upside: +1.73%
Merck & Co.
Oct 27, 2023
Upgrades: Outperform
Price Target: $132
Current: $125.77
Upside: +4.95%
Candel Therapeutics
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $6.01
Upside: -50.08%
Replimune Group
Dec 12, 2022
Maintains: Outperform
Price Target: $40 → $70
Current: $9.89
Upside: +607.79%
Eli Lilly
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $857.47
Upside: -53.82%